Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Eric Karran

More than 45 million people worldwide are estimated to have Alzheimer's disease (AD) or some type of dementia, and there are few therapeutics to help them. Although a handful of high-profile candidates are currently being tested in expensive large-scale clinical trials, the neurodegenerative space is particularly fraught with failure. As problematically, the early-stage pipeline for AD is running dry. So what happens if plan A fails again, as it has so many times in the past? Eric Karran, Director of Research at Alzheimer's Research UK, hopes that the newly launched UK£30-million Drug Discovery Alliance can shore up the community. The former head of neuroscience research at Johnson & Johnson, Eli Lilly and Pfizer tells Asher Mullard about Alzheimer's Research UK's plan to embed drug discovery teams directly into academic centres.

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Eric Karran. Nat Rev Drug Discov 14, 230–231 (2015). https://doi.org/10.1038/nrd4584

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4584

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing